Trial Profile
A trial to investigate the combination of hyaluronidase (PEGPH20) and a PD-1 inhibitor in patients with high-hyaluronan non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2015
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2015 New trial record
- 07 Jan 2015 According to a Halozyme Therapeutics media release, this trial is expected to begin in the second half of 2015.